JP2005534319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005534319A5 JP2005534319A5 JP2004526159A JP2004526159A JP2005534319A5 JP 2005534319 A5 JP2005534319 A5 JP 2005534319A5 JP 2004526159 A JP2004526159 A JP 2004526159A JP 2004526159 A JP2004526159 A JP 2004526159A JP 2005534319 A5 JP2005534319 A5 JP 2005534319A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- receptor
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 113
- 238000000034 method Methods 0.000 claims 79
- 108020003175 receptors Proteins 0.000 claims 48
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 47
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 47
- 102000005962 receptors Human genes 0.000 claims 47
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 46
- 239000002773 nucleotide Substances 0.000 claims 45
- 125000003729 nucleotide group Chemical group 0.000 claims 45
- 108091033319 polynucleotide Proteins 0.000 claims 38
- 239000002157 polynucleotide Substances 0.000 claims 38
- 102000040430 polynucleotide Human genes 0.000 claims 38
- 150000001875 compounds Chemical class 0.000 claims 34
- 239000012634 fragment Substances 0.000 claims 21
- 208000031225 myocardial ischemia Diseases 0.000 claims 21
- 230000000295 complement effect Effects 0.000 claims 17
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 16
- 239000004472 Lysine Substances 0.000 claims 16
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 16
- 208000010125 myocardial infarction Diseases 0.000 claims 16
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 16
- 238000003752 polymerase chain reaction Methods 0.000 claims 16
- 239000000556 agonist Substances 0.000 claims 13
- 239000004031 partial agonist Substances 0.000 claims 13
- 108020004414 DNA Proteins 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 208000024172 Cardiovascular disease Diseases 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 9
- 241000700159 Rattus Species 0.000 claims 9
- 230000004913 activation Effects 0.000 claims 9
- 230000000747 cardiac effect Effects 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 8
- 206010019280 Heart failures Diseases 0.000 claims 8
- 230000009084 cardiovascular function Effects 0.000 claims 8
- 238000007634 remodeling Methods 0.000 claims 8
- 210000004413 cardiac myocyte Anatomy 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 239000003446 ligand Substances 0.000 claims 7
- 230000006907 apoptotic process Effects 0.000 claims 6
- 230000009467 reduction Effects 0.000 claims 6
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims 5
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 claims 5
- 230000008859 change Effects 0.000 claims 5
- 229940095074 cyclic amp Drugs 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 230000008569 process Effects 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 4
- 208000006029 Cardiomegaly Diseases 0.000 claims 4
- 108091006027 G proteins Proteins 0.000 claims 4
- 102000030782 GTP binding Human genes 0.000 claims 4
- 108091000058 GTP-Binding Proteins 0.000 claims 4
- 230000007423 decrease Effects 0.000 claims 4
- 238000011813 knockout mouse model Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000002861 ventricular Effects 0.000 claims 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000005961 cardioprotection Effects 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 claims 2
- 150000001982 diacylglycerols Chemical class 0.000 claims 2
- 230000037041 intracellular level Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000003574 melanophore Anatomy 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229940075993 receptor modulator Drugs 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 108091027981 Response element Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000003293 cardioprotective effect Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229940125425 inverse agonist Drugs 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035485 pulse pressure Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40077402P | 2002-08-01 | 2002-08-01 | |
| PCT/US2003/023296 WO2004013285A2 (en) | 2002-08-01 | 2003-07-25 | Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005534319A JP2005534319A (ja) | 2005-11-17 |
| JP2005534319A5 true JP2005534319A5 (https=) | 2006-09-21 |
Family
ID=31495875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004526159A Pending JP2005534319A (ja) | 2002-08-01 | 2003-07-25 | 虚血性心疾患および鬱血性心不全の処置のためのヒトｇタンパク質共役レセプターおよびそのモジュレーター |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7611832B2 (https=) |
| EP (1) | EP1543025A4 (https=) |
| JP (1) | JP2005534319A (https=) |
| CN (1) | CN100473662C (https=) |
| AU (1) | AU2003259237B2 (https=) |
| CA (1) | CA2494607A1 (https=) |
| TW (3) | TW200800009A (https=) |
| WO (1) | WO2004013285A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100473662C (zh) | 2002-08-01 | 2009-04-01 | 阿瑞那制药公司 | 治疗缺血性心脏病及充血性心衰竭的人类g蛋白偶联受体及其调节物 |
| AU2005301988A1 (en) * | 2004-11-08 | 2006-05-11 | University Of Rochester | Transgenic non-human animal models of ischemia-reperfusion injury and uses thereof |
| WO2015131099A1 (en) * | 2014-02-28 | 2015-09-03 | The General Hospital Corporation | Diagnosis of multiple myeloma and lymphoma |
| CA2945706C (en) * | 2014-04-25 | 2023-10-24 | Libramen Naturals Inc. | G-protein coupled receptor 22 transformed cell lines and uses therefor |
| CN110772636B (zh) * | 2017-08-21 | 2021-03-16 | 武汉大学 | Gpr31抑制剂在制备治疗心脏缺血再灌注损伤及相关疾病药物中的应用 |
| CN114642668B (zh) * | 2020-12-21 | 2024-04-05 | 忻佑康医药科技(南京)有限公司 | 拉坦前列素的药物新用途 |
| CN119351340B (zh) * | 2024-10-31 | 2025-07-08 | 中国食品药品检定研究院(国家药品监督管理局医疗器械标准管理中心、中国药品检验总所) | 一种测定rhTSH药物生物学活性的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE335818T1 (de) * | 1995-12-28 | 2006-09-15 | Takeda Pharmaceutical | Ligand polypeptide für hypophyse g-protein gekoppeltes rezeptor-protein, deren herstellung und anwendung |
| US6555339B1 (en) * | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
| US5994097A (en) | 1997-08-28 | 1999-11-30 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding human G-protein coupled receptor |
| EP1297127A2 (en) * | 2000-05-03 | 2003-04-02 | AstraZeneca AB | Gpr22 modulators as appetite-control agents |
| WO2002006445A2 (en) | 2000-07-19 | 2002-01-24 | Deltagen, Inc. | Transgenic mice containing targeted gene disruptions |
| WO2002061432A2 (en) | 2001-02-01 | 2002-08-08 | Lifespan Biosciences, Inc. | Gpr22, a g protein-coupled receptor (gpcr) and compositions and methods related thereto |
| JP2005516605A (ja) | 2002-02-01 | 2005-06-09 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 心血管疾患を処置するための方法および組成物 |
| CN100473662C (zh) | 2002-08-01 | 2009-04-01 | 阿瑞那制药公司 | 治疗缺血性心脏病及充血性心衰竭的人类g蛋白偶联受体及其调节物 |
| CN101287832A (zh) | 2005-10-14 | 2008-10-15 | 艾尼纳制药公司 | Gpr22和其相关方法 |
-
2003
- 2003-07-25 CN CNB038234882A patent/CN100473662C/zh not_active Expired - Fee Related
- 2003-07-25 US US10/523,100 patent/US7611832B2/en not_active Expired - Fee Related
- 2003-07-25 EP EP03766914A patent/EP1543025A4/en not_active Withdrawn
- 2003-07-25 AU AU2003259237A patent/AU2003259237B2/en not_active Ceased
- 2003-07-25 CA CA002494607A patent/CA2494607A1/en not_active Abandoned
- 2003-07-25 WO PCT/US2003/023296 patent/WO2004013285A2/en not_active Ceased
- 2003-07-25 JP JP2004526159A patent/JP2005534319A/ja active Pending
- 2003-07-30 TW TW096125738A patent/TW200800009A/zh unknown
- 2003-07-30 TW TW096144624A patent/TW200815603A/zh unknown
- 2003-07-30 TW TW092120775A patent/TWI291555B/zh not_active IP Right Cessation
-
2006
- 2006-11-22 US US11/604,179 patent/US20070224127A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goetze et al. | Cardiac natriuretic peptides | |
| Mörner et al. | Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden | |
| Dadson et al. | Molecular mechanisms in cardiomyopathy | |
| Friedrichs et al. | HBEGF, SRA1, and IK: Three cosegregating genes as determinants of cardiomyopathy | |
| US9193777B2 (en) | Method of treating cardiac arrhythmia with long acting atrial natriuretic peptide(LA-ANP) | |
| US20130247233A1 (en) | G protein coupled receptors and uses thereof | |
| Perrot et al. | Mutations in NEBL encoding the cardiac Z-disk protein nebulette are associated with various cardiomyopathies | |
| Truszkowska et al. | A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations | |
| Rubattu et al. | Atrial natriuretic peptide gene variants and circulating levels: implications in cardiovascular diseases | |
| Weigl et al. | The C-terminal HCN4 variant P883R alters channel properties and acts as genetic modifier of atrial fibrillation and structural heart disease | |
| JP2005534319A5 (https=) | ||
| JP2003506042A (ja) | セクレチン様ファミリーの新規ｇｐｃｒ様分子１５５７１及びその使用 | |
| US8420321B2 (en) | Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism | |
| JP2002515223A5 (https=) | ||
| CN1662664A (zh) | Ldl受体相关蛋白1与蛋白2及对骨与软骨疾病状态的治疗 | |
| US11459613B2 (en) | Methods of characterizing resistance to modulators of Cereblon | |
| JP4510630B2 (ja) | 個体における心血管疾患を評価する方法 | |
| Ruan et al. | Restrictive cardiomyopathy resulting from a troponin I type 3 mutation in a Chinese family | |
| WO2007026874A1 (ja) | Ｇｐｒ１２０とホスホリパーゼとを用いる疾患に有用な物質のスクリーニング方法 | |
| CA2496985C (en) | Method for the identification of a risk for a thrombogenic disorder by determining the tafi -ile347 polymorphism | |
| JP5187875B2 (ja) | 心肥大ならびに拡張型心筋症非ヒトモデル動物 | |
| WO2001046414A1 (fr) | Nouvelle proteine receptrice couplee a la proteine de fixation de guanosine triphosphate, bg26 | |
| Rivera et al. | Molecular remodeling in the failing human heart | |
| Ramu et al. | Polymorphic variants of β1 adrenergic receptor gene (Ser49Gly & Arg389Gly) in healthy Tamilian volunteers | |
| JP2006525782A5 (https=) |